Guggenheim Maintains Buy on Rapport Therapeutics, Lowers Price Target to $66
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
Guggenheim analyst Delma Caiati maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and lowers the price target from $70 to $66.
Guggenheim analyst Delma Caiati maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and lowers the price target from $70 to $66.